Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naive Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

被引：0

作者：

Mascarenhas, John ^{[1
]}

Kremyanskaya, Marina ^{[2
]}

Patriarca, Andrea ^{[3
,4
]}

Gupta, Vikas ^{[5
]}

Palandri, Francesca ^{[6
]}

Devos, Timothy ^{[7
,8
]}

Rampal, Raajit K. ^{[9
]}

Talpaz, Moshe ^{[10
]}

Vannucchi, Alessandro ^{[11
]}

Kuykendall, Andrew ^{[12
]}

Kiladjian, Jean-Jacques ^{[13
]}

Verstovsek, Srdan ^{[14
]}

Mesa, Ruben ^{[15
]}

Colak, Gozde ^{[16
]}

Li, Qing ^{[17
]}

Klein, Sandra ^{[16
]}

Harrison, Claire ^{[18
]}

机构：

[1] Icahn Sch Med Mt Sinai, Dept Hematol & Med Oncol, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[3] Univ Piemonte Orientale, Dept Translat Med, Hematol Unit, Novara, Italy

[4] AOU Maggiore Carite, Novara, Italy

[5] Univ Toronto, Dept Med, Toronto, ON, Canada

[6] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seregnoli, Bologna, Italy

[7] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium

[8] Katholieke Univ Leuven, Rega Inst, Lab Mol Immunol, Leuven, Belgium

[9] Mem Sloan Kettering Canc Ctr, Ctr Hematol Malignancies, 1275 York Ave, New York, NY 10021 USA

[10] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[11] Univ Florence, Azienda Osped Univ Careggi, Florence, Italy

[12] H Lee Mofitt Canc Ctr, Dept Malignant Hematol, Tampa, FL USA

[13] Univ Paris, Hop St Louis, Paris, France

[14] MD Anderson Canc Ctr, Houston, TX USA

[15] UT Hlth San Antonio MD Anderson Canc Ctr, Mays Canc Ctr, San Antonio, TX USA

[16] Constellat Pharmaceut Inc, Boston, MA USA

[17] MorphoSys US Inc, Boston, MA USA

[18] Guys & St Thomas NHS Fdn Trust, London, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158147

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of CPI-0610 and Ruxolitinib vs. placebo and Ruxolitinib in JAKi-treatment-naive Myelofibrosis (MF) patients
Al-Ali, H. K.
Mascarenhas, J.
Harrison, C.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Humphrey, J.
Verstovsek, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 164 - 164
[22] Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna-Maria
Li, Qing
Brown, Barbara
Harrison, Claire N.
Mascarenhas, John
BLOOD, 2023, 142
[23] Exploratory Analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
Harrison, Claire
Verstovsek, Srdan
Salama, Mohamed E.
Mascarenhas, John
Talpaz, Moshe
Mesa, Ruben
Vannucchi, Alessandro M.
Rampal, Raajit K.
Oh, Stephen
Olteanu, Horatiu
Chiu, April
Chen, Dong
Hanson, Curtis A.
Curto-Garcia, Natalia
Taverna, Pietro
Cui, Jike
Zavidij, Oksana
Chang, Tzuu-Wang
Colak, Gozde
Efuni, Sergey
Keller, Patricia
Trojer, Patrick
Mead, Adam J.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 27 - 28
[24] Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naive patients with myelofibrosis: Updated results from XPORT-MF-034
Ali, Haris
Kishtagari, Ashwin
Maher, Keri Renee
Mohan, Sanjay
Prchal, Josef T.
Wang, Xulong
Chamoun, Kamal
Tantravahi, Srinivas Kiran
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naive Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034
Ali, Haris
Kishtagari, Ashwin
Maher, Keri
Mohan, Sanjay
Prchal, Josef
Wang, Xulong
Chamoun, Kamal
Tantravahi, Srinivas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S389 - S389
[26] CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS (MF) PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR (JAKI): UPDATE FROM PHASE 2 MANIFEST STUDY
Vannucchi, A.
Talpaz, M.
Rampal, R.
Verstovsek, S.
Harrison, C.
Drummond, M.
Kremyanskaya, M.
Schiller, G.
Patriarca, A.
Van Gorkom, G.
Bose, P.
Hoffman, R.
Palandri, F.
Iurlo, A.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Mascarenhas, J.
HAEMATOLOGICA, 2021, 106 (10) : 52 - 52
[27] Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naive Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
Mascarenhas, John
Rampal, Raajit K.
Vannucchi, Alessandro M.
Gupta, Vikas
Oh, Stephen T.
Kuykendall, Andrew T.
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Kremyanskaya, Marina
Scandura, Joseph
Kraeft, Tabea
Eliane, Jean-Pierre
Chang, Tzuu-Wang
Cui, Jike
Kuffer, Christian
Boxhammer, Rainer
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S417 - S418
[28] Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-na<spacing diaeresis>ive patients with myelofibrosis
Rampal, Raajit
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron Thomas
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Kuykendall, Andrew Tucker
Mesa, Ruben A.
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Wu, Manlei
Brown, Barbara
Harrison, Claire
Mascarenhas, John
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
Mead, Adam
Mascarenhas, John
Gerds, Aaron
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Humphrey, Jeffrey
Verstovsek, Srdan
Harrison, Claire
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 101 - 102
[30] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
Yacoub, Abdulraheem
Erickson-Viitanen, Sue
Zhou, Feng
Assad, Albert
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 115 - 116

← 1 2 3 4 5 →